Page last updated: 2024-11-05

ticlopidine and Circulatory Collapse

ticlopidine has been researched along with Circulatory Collapse in 2 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Shavadia, J	1
Welsh, R	1
Gershlick, A	1
Zheng, Y	1
Huber, K	1
Halvorsen, S	1
Steg, PG	1
Van de Werf, F	1
Armstrong, PW	1
Elad, S	1
Chackartchi, T	1
Shapira, L	1
Findler, M	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]			Phase 3	1,899 participants (Actual)	Interventional	2008-03-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	50
Primary PCI (Group B)	43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	59
Primary PCI (Group B)	73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	100
Primary PCI (Group B)	123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	117
Primary PCI (Group B)	135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	77
Primary PCI (Group B)	85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	43
Primary PCI (Group B)	42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	116
Primary PCI (Group B)	135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	31
Primary PCI (Group B)	32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	41
Primary PCI (Group B)	56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	57
Primary PCI (Group B)	72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	9
Primary PCI (Group B)	2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	6
Primary PCI (Group B)	3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	61
Primary PCI (Group B)	45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	206
Primary PCI (Group B)	191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	23
Primary PCI (Group B)	21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	45
Primary PCI (Group B)	41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	19
Primary PCI (Group B)	11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	1
Primary PCI (Group B)	2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	32
Primary PCI (Group B)	38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	10
Primary PCI (Group B)	29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	2
Primary PCI (Group B)	0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	7
Primary PCI (Group B)	4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	8
Primary PCI (Group B)	1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	267
Primary PCI (Group B)	236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Tenecteplase (Group A)	15
Primary PCI (Group B)	5

Other Studies

2 other studies available for ticlopidine and Circulatory Collapse

Article	Year
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6 Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F	2016
A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet. Journal of clinical periodontology, 2008, Volume: 35, Issue:4 Topics: Aspirin; Clopidogrel; Drug Combinations; Female; Gingival Hemorrhage; Humans; Middle Aged; Periodont	2008

Article

Year

Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)

Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016

A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet.

Journal of clinical periodontology, 2008, Volume: 35, Issue:4

Topics: Aspirin; Clopidogrel; Drug Combinations; Female; Gingival Hemorrhage; Humans; Middle Aged; Periodont

2008